This was the stock's second consecutive day of losses.
Investor's Business Daily on MSN1h
Supernus Pharmaceuticals Hits 80-Plus Relative Strength Rating BenchmarkSupernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81. Please watch the ...
Investor's Business Daily on MSN10d
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit WinAnd Catalyst Pharmaceuticals stock is one of those that seems to be thriving. Catalyst is Thursday's selection for IBD 50 ...
Catalyst Pharmaceuticals Stock Performance Catalyst Pharmaceuticals stock opened at $24.46 on Thursday. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of 20.73, a price-to ...
Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The Russell 2000 ...
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven ...
Catalyst has been a top-rated stock at MAPsignals for a few years. That means the stock has unusual buy pressure and growing ...
Highlights:,Institutional investors, including the Swiss National Bank, have adjusted their stakes in,Catalyst ...
A major breakthrough in liquid catalysis is transforming how essential products are made, making the chemical manufacturing ...
Shares of Catalyst Pharmaceuticals Inc. CPRX shed 1.43% to $24.11 Thursday, on what proved to be an all-around grim trading ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback